Contec Medical Systems Co.,Ltd (SHE:300869)
China · Delayed Price · Currency is CNY 15.15
-0.13 (-0.85%)
At close: Feb 13, 2026
SHE:300869 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Operating Revenue | 486.18 | 476.07 | 742.65 | 708.68 | 904.84 | 1,396 |
Other Revenue | 3.73 | 3.73 | 4.25 | 3.43 | 3.87 | 4.79 |
| 489.91 | 479.81 | 746.9 | 712.11 | 908.71 | 1,401 | |
Revenue Growth (YoY) | 5.68% | -35.76% | 4.88% | -21.63% | -35.15% | 261.84% |
Cost of Revenue | 344.99 | 356.53 | 359.82 | 382.12 | 476.88 | 591.54 |
Gross Profit | 144.92 | 123.27 | 387.08 | 330 | 431.83 | 809.69 |
Selling, General & Admin | 148.6 | 125.28 | 155.58 | 122.4 | 95.53 | 92.05 |
Research & Development | 90.8 | 105.16 | 110.6 | 93.25 | 66.06 | 48.74 |
Other Operating Expenses | 0.27 | 3.42 | -14.44 | 3.78 | -2.84 | -9.23 |
Operating Expenses | 240.04 | 235.3 | 250.71 | 221.45 | 159.13 | 132.61 |
Operating Income | -95.12 | -112.03 | 136.38 | 108.55 | 272.7 | 677.08 |
Interest Expense | -35.3 | -35.3 | -45.1 | -19.08 | -2.86 | -2.42 |
Interest & Investment Income | 60.9 | 71.06 | 92.65 | 92.23 | 68.64 | 34.79 |
Currency Exchange Gain (Loss) | 6.66 | 6.66 | -2.95 | -13.31 | 60.92 | -13.73 |
Other Non Operating Income (Expenses) | -2.62 | -1.96 | -2.23 | -1.5 | -0.94 | -1.52 |
EBT Excluding Unusual Items | -65.48 | -71.58 | 178.75 | 166.89 | 398.45 | 694.2 |
Gain (Loss) on Sale of Investments | 4 | 1.59 | 2.02 | 46.64 | - | - |
Gain (Loss) on Sale of Assets | 0.01 | 0.17 | -0.07 | -0.26 | -0.04 | -0 |
Asset Writedown | -9.65 | -0.25 | - | -0.01 | -0.02 | -0 |
Other Unusual Items | -3.81 | -3.81 | 5.42 | 6.14 | 9.61 | 21.27 |
Pretax Income | -74.93 | -73.89 | 186.13 | 219.39 | 407.99 | 715.47 |
Income Tax Expense | 3.47 | 4.02 | 20.36 | 23.19 | 55.64 | 102.08 |
Net Income | -78.41 | -77.9 | 165.77 | 196.2 | 352.35 | 613.4 |
Net Income to Common | -78.41 | -77.9 | 165.77 | 196.2 | 352.35 | 613.4 |
Net Income Growth | - | - | -15.51% | -44.32% | -42.56% | 731.37% |
Shares Outstanding (Basic) | 409 | 410 | 404 | 400 | 402 | 374 |
Shares Outstanding (Diluted) | 409 | 410 | 414 | 409 | 402 | 374 |
Shares Change (YoY) | 1.11% | -1.06% | 1.39% | 1.73% | 7.43% | 1.39% |
EPS (Basic) | -0.19 | -0.19 | 0.41 | 0.49 | 0.88 | 1.64 |
EPS (Diluted) | -0.19 | -0.19 | 0.40 | 0.48 | 0.88 | 1.64 |
EPS Growth | - | - | -16.67% | -45.26% | -46.53% | 720.00% |
Free Cash Flow | -3.34 | 7.88 | 150.28 | 22.21 | -101.66 | 509.06 |
Free Cash Flow Per Share | -0.01 | 0.02 | 0.36 | 0.05 | -0.25 | 1.36 |
Dividend Per Share | 0.250 | 0.250 | 0.300 | 0.125 | 0.300 | 0.250 |
Dividend Growth | -16.67% | -16.67% | 140.00% | -58.33% | 20.00% | - |
Gross Margin | 29.58% | 25.69% | 51.82% | 46.34% | 47.52% | 57.78% |
Operating Margin | -19.42% | -23.35% | 18.26% | 15.24% | 30.01% | 48.32% |
Profit Margin | -16.00% | -16.24% | 22.19% | 27.55% | 38.77% | 43.78% |
Free Cash Flow Margin | -0.68% | 1.64% | 20.12% | 3.12% | -11.19% | 36.33% |
EBITDA | -68.8 | -86.04 | 161.92 | 127.51 | 290.34 | 692.25 |
EBITDA Margin | -14.04% | -17.93% | 21.68% | 17.91% | 31.95% | 49.40% |
D&A For EBITDA | 26.33 | 25.99 | 25.54 | 18.96 | 17.64 | 15.17 |
EBIT | -95.12 | -112.03 | 136.38 | 108.55 | 272.7 | 677.08 |
EBIT Margin | -19.42% | -23.35% | 18.26% | 15.24% | 30.01% | 48.32% |
Effective Tax Rate | - | - | 10.94% | 10.57% | 13.64% | 14.27% |
Revenue as Reported | 489.91 | 479.81 | 746.9 | 712.11 | - | 1,401 |
Advertising Expenses | - | 7.76 | 8.32 | 3.8 | 6.21 | 2.26 |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.